文献速递血管炎

阿那白滞素在巨细胞动脉炎中的激素节约效应:长期临床、生物学与影像学评估病例系列

Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

这项回顾性病例系列分析了法国大血管血管炎研究组中6例激素依赖或抵抗的巨细胞动脉炎(GCA)患者,使用阿那白滞素(IL-1受体拮抗剂)中位19个月后全部达到临床和生物学缓解,4例大血管受累者中1例主动脉炎消失、3例血管摄取减少,中位随访56个月时4例停用激素、2例减至5 mg/天。

要点

  • 阿那白滞素可使激素依赖或抵抗的GCA患者达到临床和生物学缓解。
  • 大血管受累者中,阿那白滞素可能改善主动脉炎和血管摄取。
  • 延长注射间隔至每48小时可致1例在引入后13个月复发。

核心结论

  • 在这组短系列中,阿那白滞素似乎是难治性GCA有效且安全的激素节约药物,并可能对大血管受累有益。

研究设计与样本

  • 回顾性研究,分析法国大血管血管炎研究组中所有接受阿那白滞素治疗的GCA患者,共6例,其中4例分析主动脉炎结局。

主要发现

  • 阿那白滞素治疗中位持续19(18-32)个月后,全部6例患者达到完全临床和生物学缓解。
  • 4例大血管受累患者中,1例主动脉炎消失,3例血管摄取减少。
  • 中位随访56(48-63)个月后,4例停用糖皮质激素,2例剂量减至5 mg/天。
  • 1例在阿那白滞素引入后13个月、因将每日注射间隔延长至每48小时而复发。
  • 3例出现一过性注射部位反应,1例发生肺炎。

临床怎么用

  • 对激素依赖或抵抗的GCA患者,可考虑阿那白滞素作为激素节约治疗选择。
  • 使用阿那白滞素期间需监测注射部位反应和感染事件。
  • 不应随意延长阿那白滞素注射间隔至每48小时,以免诱发复发。

局限性

  • 本研究为回顾性病例系列,样本量仅6例,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The treatment of GCA relies on corticosteroids but is burdened by a high rate of relapses and adverse effects. Anti-IL-6 treatments show a clear benefit with a significant steroid-sparing effect, but late relapses occur after treatment discontinuation. In addition to IL-6, IL-1 also appears to play a significant role in GCA pathophysiology. We report herein the efficacy of anakinra, an IL-1 receptor antagonist, in six GCA patients exhibiting corticosteroid dependence or resistance, specifically analysing the outcome of aortitis in four of them. METHODS: This retrospective study analysed the cases of all GCA patients treated with anakinra from the French Study Group for Large Vessel Vasculitis. RESULTS: After a median duration of anakinra therapy of 19 (18-32) months, all six patients exhibited complete clinical and biological remission. Among the four patients with large-vessel involvement, one had a disappearance of aortitis under anakinra and three showed a decrease in vascular uptake. After a median follow-up of 56 (48-63) months, corticosteroids were discontinued in four patients, and corticosteroid dosage could be decreased to 5 mg/day in two patients. One patient relapsed 13 months after anakinra introduction in the context of increasing the daily anakinra injection interval to every 48 h. Three patients experienced transient injection-site reactions, and one patient had pneumonia. CONCLUSION: In this short series, anakinra appears to be an efficient and safe steroid-sparing agent in refractory GCA, with a possible beneficial effect on large-vessel involvement.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Deshayes S, Ly KH, Rieu V, et al. Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments. Rheumatology (Oxford). 2021. PMID: 33742671. doi:10.1093/rheumatology/keab280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。